Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19

Statement Herbal Remedies Medicines
  • Version
  • Download 20514
  • File Size 663.66 KB
  • File Count 4
  • Create Date 13 July 2020
  • Last Updated 21 August 2020

Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19

Herbal-based traditional medicines or phytomedicines play a significant role in disease management in Africa and are widely used as alternative medicines. Therefore, it is important to evaluate both the safety and efficacy of these indigenous botanical assets in medicine prior to endorsing their use by the medical community and the public. There have been several declarations by institutions in Member States on the use of herbal-based traditional medicine for the prevention of SARS-CoV-2 transmission or treating people with a presumptive or definitive diagnosis of coronavirus disease 2019 (COVID-19). Many of the claims are difficult to verify because of the lack of documented evidence showing that these remedies prevent or clear SARS-CoV-2 infection and/or improve clinical outcomes of those suffering from COVID-19. As the pandemic continues to spread in Africa, there are increasing messages promoting the use of herbal-based traditional medicines for COVID-19. Currently, no herbal remedy has been validated for use to prevent or treat COVID19. Herbal remedies or medicines are naturally occurring, plant-derived substances that are developed mostly through a process with minimal or no respect for good clinical practice (GCP).

Attached Files

FileAction
Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19 PORTUGUESEDownload
Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19 FRENCHDownload
Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19 ENGLISHDownload
Statement on Herbal Remedies and Medicines for Prevention and Treatment of COVID-19 ARABICDownload

This slide deck, presented at the Developing Countries Vaccine Manufacturers Network International Annual General Meeting in October 2024, describes updated results from a study to assess the current and planned state of vaccine manufacturing in Africa and provides insights into what’s needed to develop a robust and sustainable vaccine manufacturing ecosystem.

We surveyed African vaccine manufacturers to better understand their current manufacturing capacity and capabilities, the progress they’ve made since 2023, and their future outlooks. This information can help stakeholders and funders better coordinate and prioritize actions to build a successful African vaccine manufacturing ecosystem.

Corporate author(s): Africa Centres for Disease Control and Prevention (Africa CDC); Clinton Health Access Initiative (CHAI); PATH

Publication date: October 2024

Download Files
FileAction
African Vaccine Manufacturing Mapping | Supply and Demand LandscapeDownload